Developing cardiac and skeletal muscle share fast-skeletal myosin heavy chain and cardiac troponin-I expression by Clause, KC et al.
Developing Cardiac and Skeletal Muscle Share Fast-
Skeletal Myosin Heavy Chain and Cardiac Troponin-I
Expression
Kelly C. Clause1,2., Jason Tchao1,2., Mary C. Powell1, Li J. Liu1,3, Johnny Huard4,5, Bradley B. Keller6,
Kimimasa Tobita1,2,3,5*
1Cardiovascular Development Research Program, Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh,
Pennsylvania, United States of America, 2Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 3Department of
Developmental Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 4Department of Orthopedic Surgery, University of Pittsburgh,
Pittsburgh, Pennsylvania, United States of America, 5McGowan Institutes for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of
America, 6Department of Pediatrics, University of Louisville, Louisville, Kentucky, United States of America
Abstract
Skeletal muscle derived stem cells (MDSCs) transplanted into injured myocardium can differentiate into fast skeletal muscle
specific myosin heavy chain (sk-fMHC) and cardiac specific troponin-I (cTn-I) positive cells sustaining recipient myocardial
function. We have recently found that MDSCs differentiate into a cardiomyocyte phenotype within a three-dimensional gel
bioreactor. It is generally accepted that terminally differentiated myocardium or skeletal muscle only express cTn-I or sk-
fMHC, respectively. Studies have shown the presence of non-cardiac muscle proteins in the developing myocardium or
cardiac proteins in pathological skeletal muscle. In the current study, we tested the hypothesis that normal developing
myocardium and skeletal muscle transiently share both sk-fMHC and cTn-I proteins. Immunohistochemistry, western blot,
and RT-PCR analyses were carried out in embryonic day 13 (ED13) and 20 (ED20), neonatal day 0 (ND0) and 4 (ND4),
postnatal day 10 (PND10), and 8 week-old adult female Lewis rat ventricular myocardium and gastrocnemius muscle.
Confocal laser microscopy revealed that sk-fMHC was expressed as a typical striated muscle pattern within ED13 ventricular
myocardium, and the striated sk-fMHC expression was lost by ND4 and became negative in adult myocardium. cTn-I was
not expressed as a typical striated muscle pattern throughout the myocardium until PND10. Western blot and RT-PCR
analyses revealed that gene and protein expression patterns of cardiac and skeletal muscle transcription factors and sk-
fMHC within ventricular myocardium and skeletal muscle were similar at ED20, and the expression patterns became cardiac
or skeletal muscle specific during postnatal development. These findings provide new insight into cardiac muscle
development and highlight previously unknown common developmental features of cardiac and skeletal muscle.
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Introduction
Muscles are composed of different fiber types to fulfill various
functional needs. Fiber types are categorized generally according
to their specific myosin heavy chain (MHC) isoforms. In rats, there
are four major isoforms of MHC, one slow type (type I/ß) and
three fast types: IIa, IIx/IId, and IIb, which is equivalent to
skeletal muscle specific fast myosin heavy chain (sk-fMHC). An
individual muscle fiber can contain just one myosin isoform or
mixtures of two or more different isoforms [1,2,3]. An additional
MHC isoform, a, is present in the myocardium. Different MHC
isoforms are expressed in both tissue and stage-specific manners,
and much work has been done to show the relative change in the
expression ratio of a-MHC: ß-MHC in the myocardium during
development and with intervention. During the early myofibrillo-
genesis of nascent cardiomyocytes, non-cardiac MHC plays an
important role in assembling sarcomere structure [4]. However,
little investigation into the expression of skeletal muscle specific
MHCs in the developing myocardium has been done.
Troponins are proteins that regulate the thin filament system in
skeletal and cardiac muscle and form part of the contractile
complex. Troponin I is encoded by 3 different genes and is
expressed differentially in various types of tissue. However, cardiac
troponin I (cTn-I) is uniquely expressed in the heart and is distinct
from the fast and slow forms in skeletal muscle [5].
It has been widely accepted that terminally differentiated
mature cardiac muscle does not express proteins that are specific
to skeletal muscle. However, studies have shown that several
skeletal muscle specific proteins, such as skeletal muscle specific
troponins, are transiently present in the developing heart [6].
Similarly, ‘‘cardiac’’ and ‘‘skeletal’’ excitation-contraction coupling
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mechanisms co-exist in developing skeletal muscle with the
‘‘cardiac’’ type dominant in the early phases of myogenesis and
the ‘‘skeletal’’ dominating in more mature muscle [7,8]. These
studies suggest the coexistence of many cardiac and skeletal muscle
specific proteins and excitation-contraction coupling mechanisms
within both developing tissue and cultured cells, particularly those
that are considered to be immature. While the idea that skeletal
and cardiac muscle share partially overlapping developmental
profiles is not new, reports of expression of specific structural
protein isoforms have varied across studies. For example,
Fougerousse et al. concluded that the cardiac isoform of myosin
binding protein C, cardiac MyBP-C, is strictly specific to the heart
during murine and human development [9]. However, it is
reported to be expressed in developing chick skeletal muscle
[10,11,12]. Factors such as experimental conditions, differences
across species, and developmental time points examined can lead
to these differences in results. Moreover, while these phenotypic
changes have been studied during early cardiac morphogenesis
period, few have focused on the transition that occurs between late
fetal and early postnatal life.
In our previous studies of murine or human skeletal muscle
derived stem cell (MDSC) transplantation into infarcted mouse
myocardium, we found that MDSC transplanted post-infarcted
myocardium sustains its contractile function, preventing left
ventricular chamber remodeling, and some transplanted donor
MDSCs differentiate into both sk-fMHC and/or cTn-I positive
muscle cells [13,14]. We have recently shown MDSCs can
differentiate into cells with an immature functioning cardiomyo-
cyte phenotype within a three-dimensional engineered tissue
construct [15]. However, MDSC derived cardiomyocytes gener-
ated in vitro are biochemically and functionally more similar to fetal
rather than mature cardiomyocytes. While stem cell derived
cardiomyocytes show promise, the sequence of events that lead to
terminal cardiomyocyte differentiation and functional maturation
is as of yet poorly understood [16]. The use of stem-cell derived
cardiomyocytes for tissue engineering and regenerative medicine
applications would clearly benefit from a better understanding of
the biochemical and structural changes that lead to cardiac and
skeletal muscle specification during natural development. Howev-
er, it remains to be seen whether MDSC derived sk-fMHC
positive cells are terminally differentiating skeletal muscle cells or
potentially differentiating cardiomyocytes. In order to help address
the question, we investigated the presence of sk-fMHC and cTn-I
within the native developing myocardium and skeletal muscle in a
rat animal model.
Materials and Methods
The presence of sk-fMHC and cTn-I from embryonic day (ED)
13 and 20, neonatal day (ND) 0 and 4, postnatal day (PND) 10,
and 8 week-old adult female Lewis rat ventricular myocardium
and skeletal muscle (hind limb in ED13, ED20, ND0 and ND4,
and gastrocnemius and soleus muscles in PND10 and adult) was
assessed using immunohistochemistry, western blot, and RT-PCR.
Our research protocol followed the National Institutes of Health
(NIH) guidelines for animal care and was approved by the
University of Pittsburgh’s Institutional Animal Care and Use
Committee.
Construction of 3-dimensional Collagen Gel Bioreactor
from Rat Skeletal Muscle Derived Stem Cells (MDSCs)
We isolated skeletal muscle derived stem cells (MDSCs) from 3
post-natal day 10 Lewis rat gastrocnemius muscle using a preplate
technique [15]. Isolated MDSCs were expanded on a rat-tail
collagen type-1 (Invitrogen, Carlsbad, CA, USA) coated flask (T-
75, Fisher Scientific, Pittsburgh, PA) and a 3-dimensional collagen
gel bioreactor was constructed using a mixture of MDSCs and rat
tail collagen type-I (Invitrogen) with Matrigel (BD bioscience, San
Jose, CA, USA), and a Flexcell 4000TT system (Flexcell
International, Inc. Hillsborough, NC, USA) [15]. The constructed
collagen gel tissue was cultured for 9 days and the tissue was
harvested for histological assessment and the gene expression [15].
Immunohistochemical Staining
Heart and skeletal muscle samples, and MDSC-collagen gel
constructs (N= 4) were fixed with 4% paraformaldehyde/PBS for
15 minutes (EDs 13 and 20, N=4 in each developmental stage) to
12 hours (ND0 to adult) and embedded in 13% polyacrylamide
gel. The 100 (ND4 and adult) to 150 mm (ED13, ED20, ND0)
thick sections were made using a vibratory microtome (Vibratome-
1000, Vibrotome.com) [17] and stained for mouse monoclonal sk-
fMHC (Sigma MY32, St. Louis, MO, USA, 1:200 dilution) and
mouse monoclonal cardiac specific Troponin-I [cTn-I, Abcam
(19C7), Cambridge, MA, USA, 1:100 dilution] primary antibodies
and Alexa Fluor 488 IgG2b or Alexa Fluor 594 IgG1 goat anti-
mouse secondary antibodies (Invitrogen, Carlsbad, CA, USA,
1:200 final concentration). The stained sections were optically
scanned with a Z-stack imaging protocol (from 20 to 30 optical
sectioning/filed) by using a standard laser scanning confocal
microscope (FV1000, Olympus, Tokyo, Japan) [17]. Imaging
fields (at least 5 different fields/sample) were randomly selected
and the acquired image stack was used to make a 3D projection
image using Image-J software (NIH).
SDS-PAGE and Immunoblotting
Freshly frozen heart, skeletal muscle, and MDSC-collagen gel
constructs (n = 3) samples were used. Protein was extracted from
pooled samples, and immunoblotting was carried out using routine
protocols. Each lane contained 20 mg of total protein. Mouse
monoclonal a-sarcomeric actinin (Sigma, EA53, 1:500 dilution),
mouse monoclonal cardiac troponin-I (Abcam, 1:100 dilution),
and mouse monoclonal sk-fMHC (Sigma MY32, 1:500 dilution)
were visualized with IR-Dye 800 donkey anti-mouse secondary
antibody (IgG1 and IgG2b, Rockland Immunochemicals, Gilberts-
ville, PA, USA, 1:10,000 dilution). All proteins were visualized
using an infrared western blot imaging system (Odyssey, LI-COR
Biosciences Lincoln, NE, USA). Immunoblots were performed in
either quintuplicate or triplicate [ED 13 (n = 30), ED 20 (n= 5),
ND 0 (n= 5); n = 3 for ND4 (n= 3), PND 10 (n = 3), and adult rats
(n = 3)] [15].
RT-PCR and Real-time RT-PCR
Freshly frozen pooled ventricular myocardium, skeletal muscle
samples [ED13 (n = 10), ED20 and ND0 (n = 5), ND4, PND10,
and adult (n = 3)], and MDSC-collagen gel constructs (n = 3) were
used. Total RNA was prepared using Trizol solution (Invitrogen)
and treated with TURBO DNA-free kit (Ambion, Austin, TX,
USA). Primers, whose target genes were, Nkx2.5, GATA4, MyoD,
Myogenin, sk-fMHC (MYH4), a-MHC (MYH7), cardiac tropo-
nin-I (Tnn3), were obtained from Qiagen Quanti-Tect Primer
Assay (Qiagen, Valencia, CA). One-step reverse transcription (RT)
was performed with a total amount of 1 mg RNA in a total volume
of 25 mL that used MuLy (Roches, Pleasanton, CA, USA). The
following program was used for RT: 42uC 15 minutes, 99uC 5
minutes, 5uC 5 minutes, for 1 cycle. The produced cDNA (1 mL)
was used for RT-PCR (94uC 2 minutes, 95uC 50 seconds, 58uC 30
seconds, 72uC 1 minute, for 30 cycles followed by 72uC 7 minutes
extension) or real-time RT-PCR (50uC for 2 minutes, 95uC for 10
sk-fMHC and cTn-I in Developing Striated Muscle
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minutes, 95uC for 15 seconds, 60uC for 1 minute, 95uC for 15
minutes, 60uC for 15 minutes for 40 cycles). For normalization of
real-time PCR results, b-actin was used as an internal control. All
PCR products were confirmed by University of Pittsburgh DNA
Sequence Core Facilities, performed by Eppendorf Mastercycles.
All real-time PCR assays were completed in triplicate (n = 3 in
each developmental stage). Real-time PCR samples were pro-
cessed using Applied Biosystems HT7900 system.
Results
Differentiating MDSCs in a 3-dimensional collagen/extracellu-
lar matrix gel construct displayed spontaneous beating activity
from culture day 5 and formed a muscle tissue by culture day 7
similarly to our previous study [15]. Confocal microscopy showed
that the differentiating cardiomyocyte-like cells co-expressed
skeletal muscle specific fast myosin heavy chain (sk-fMHC) and
cardiac specific troponin-I (cTn-I) as a typical striated muscle
Figure 1. sk-fMHC (green color) and cardiac troponin-I (red color) expression (Panel A) and gene expression (Panel B) of skeletal
muscle derived stem cell 3D collagen gel bioreactor (MDSC-3DGB). MDSC-3DGB showed co-localized expression of sk-fMHC and cardiac
troponin I. Transcription factor and structural gene expression was increased compared to 2D undifferentiated MDSCs. Scale in panel A indicates
20 mm.
doi:10.1371/journal.pone.0040725.g001
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Figure 2. sk-fMHC (green color) and cardiac troponin-I (red color) expression within developing ventricular myocardium and
skeletal muscle. The skeletal muscle fast myosin heavy chain (sk-fMHC) and cardiac troponin-I (cTn-I) expression within the embryonic day (ED13)
heart (ED13 Ventricle insert, scale indicates 500 mm). The sk-fMHC was expressed as a typical striated muscle pattern in the developing ventricle and
sk-fMHC and cTn-I in Developing Striated Muscle
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pattern (Figure 1, panel A). Real time RT-PCR showed that
both cardiac and skeletal muscle transcription factors, cardiac sk-
fMHC, cardiac a-myosin heavy chain, and cTn-I genes are up-
regulated compared to undifferentiated MDSC (Figure 1, panel
B).
In the native rat heart, sk-fMHC was expressed as a typical
striated muscle pattern throughout the entire ventricular myocar-
dium at ED13, and cTn-I was very weakly expressed (close to
background) (Figure 2). Within ED13 somite, sk-fMHC was
expressed as a striated thin fiber-like pattern, while cTn-I was
diffusely expressed. At ED20 and ND0, striated sk-fMHC
expression was restricted to the ventricular papillary muscle and
losing striated muscle pattern in the myocardial wall (Figure 2).
cTn-I was very weakly expressed without striation in the majority
of the myocardial wall and some striated cTn-I expression pattern
was identified in the myocardium close to LV apex (Data not
shown). At ND4, sk-fMHC was still expressed in the LV
myocardium (Figure 2). However, striated pattern was complete-
ly lost. cTn-I expression increased. The PND10 LV myocardium
did not express sk-fMHC, whereas cTn-I was expressed with a
typical striated pattern. Conversely, PND10 skeletal muscle
expressed sk-fMHC as a typical striated muscle pattern and did
not express cTn-I (Figure 2).
Western blot analysis indicated that in the myocardium, sk-
fMHC was expressed in decreasing amounts until PND10
(juvenile) and was not expressed in the adult myocardium (8
week-old), whereas cTn-I was expressed in increasing amounts at
all developmental stages. In skeletal muscle, sk-fMHC was
expressed at all developmental stages, while cTn-I was expressed
very weakly at ED13 and the expression increased at ED20,
decreased at ND0, and became negative after ND4 (Figure 3).
RT-PCR analysis (30 PCR cycles, Figure 4) showed that in
ventricular myocardium, cardiac transcription factors, Nkx2.5 and
GATA4, were expressed through all developmental stages and
were also expressed in gradually decreasing levels in skeletal
muscle. Skeletal muscle transcription factor MyoD was detected at
30 PCR cycles in skeletal muscle at all developmental stages and in
ventricular myocardium until ND0. Another major skeletal muscle
transcription factor, myogenin, was expressed in both ventricular
myocardium and skeletal muscle in all developmental stages. The
sk-fMHC mRNA was expressed in ND0 myocardium, and the
expression was significantly decreased at ND4. It was then
negative in PND10 and adult ventricular myocardium. The sk-
fMHC mRNA was expressed at all developmental stages in the
skeletal muscle. The cardiac specific a-myosin heavy chain (a-
MHC) was present in the ventricular myocardium at all
developmental stages and ED13 skeletal muscle. Conversely,
postnatal and adult skeletal muscle did not express a-MHC. cTn-I
mRNA was expressed in ventricular myocardium in all develop-
mental stages and ED13, ED20 and ND0 skeletal muscle, and
became negative in PND10 and adult skeletal muscle.
We semi-quantified the changes in mRNA levels of the genes
described above by real-time RT-PCR. Table 1 shows cycle to
threshold (Ct) values of cardiac and skeletal muscle transcription
factors, structural muscle protein, and b-actin mRNA of embry-
onic day 13 ventricular myocardium and skeletal muscle (limb).
Although the Ct value of each transcription factor and structural
protein mRNA varied, these gene expression patterns overlapped
between both types of muscle tissues. During development, cardiac
transcription factor, Nkx2.5 and GATA4, expression levels in
postnatal ventricular myocardium remained at the same levels as
ED13. The mRNA level of the skeletal muscle transcription factor,
MyoD in the ventricular myocardium was elevated at ND0 and
ND4 but remained the same as ED13 in postnatal stages, whereas
the mRNA level of another skeletal muscle transcription factor,
myogenin, was significantly decreased postnatally. In developing
skeletal muscle, Nkx2.5 and GATA4 expression levels were
significantly decreased, while MyoD and myogenin expression
levels were transiently decreased at ND4 and were maintained at
the same levels during the development (Figure 5). The sk-fMHC
level in the myocardium increased from ED13 to ED20 and
maintained a steady level thereafter, while it continuously
increased in skeletal muscle. Conversely, cTn-I and a-MHC levels
were significantly increased in postnatal ventricular myocardium.
In skeletal muscle, cTn-I was increased at ND4 and adult, while a-
MHC was decreased at ED20 and thereafter it was unchanged in
postnatal development (Figure 6).
Discussion
In the current study, we found that skeletal muscle specific fast
myosin heavy chain (sk-fMHC) is transiently expressed in the
developing immature myocardium, and cardiac troponin I (cTn-I)
is transiently expressed in developing skeletal muscle. A number of
previous studies have looked at an assortment of myosin and
cTn-I expression was near background level at ED13. Somites also express sk-fMHC as a fiber structure and cTn-I was also expressed very weakly
similar to the heart (ED13 somite panel). Scales in ED13 ventricle and somite panels indicate 20 mm. At ED20, both heart muscle (ED20 Left Vent Pap
M) and skeletal muscle (not shown) express sk-fMHC and cTn-I as a striated muscle pattern. Scales in ED20 and ND4 Vent Pap M panels indicate
20 mm. In the heart, sk-fMHC expression is significantly decreased, and cTn-I expression was increased with striation pattern after neonate day 4, and
skeletal muscle significantly decreases its cTn-I expression after neonate day 4 (data not shown). At postnatal day 10 (PND10), left ventricular
myocardium does not express sk-fMHC and cTn-I displayed a typical striation pattern (PND10 Left Ventricle panel). Conversely, gastrocnemius muscle
expressed sk-fMHC as a typical striation pattern and cTn-I was negative (PND10 skeletal muscle panel). Scales in PND10 panels indicate 20 mm.
doi:10.1371/journal.pone.0040725.g002
Figure 3. Western blot analysis of developing myocardium and
skeletal muscle. Lane 1: ED13; Lane 2: ED20; Lane 3: ND0; Lane 4:
ND4; Lane 5: PND10; Lane 6: Adult (8 week-old). Top panel: Left
ventricular myocardium, Bottom panel: hind limbs at ED13, ED20,
ND0, and ND4, and gastrocnemius muscle in PND10 and adult. At ED13
and ED20, left ventricular myocardium expressed sk-fMHC and cTn-I
expression was very weak while skeletal muscle expressed sk-fMHC.
During development, sk-fMHC expression in the left ventricular
myocardium decreased and increased in skeletal muscle, whereas
cTn-I is expressed in the left ventricular myocardium and was negative
in skeletal muscle. a-sarcomeric actinin (a-sarcActn) was used to adjust
the total protein loading for the electrophoresis.
doi:10.1371/journal.pone.0040725.g003
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troponin expression patterns in both the cardiac and skeletal
muscle. a-MHC was found in both normal adult diaphragm and
stimulated fast twitch muscles in the rabbit, human masseter and
extraocular muscles, as well as the bag fibers of human, rat, and
cat muscle spindles [18,19]. From the opposite perspective, anti-
anterior latissimus dorsi myosin antibodies showed specific
reactivity with the cells of the conduction system in the rabbit
heart [20]. Similarly, there is abundant evidence that myosin
expression undergoes transitions during the development of both
skeletal and cardiac muscle in a number of species. Sweeney et al.
found that the earliest MHC detectable in both forms of striated
muscle in chick embryos (cardiac and skeletal) was indistinguish-
able from cardiac ventricular myosin expressed in the adult heart
but immunologically distinct from myosins expressed in later
embryonic and adult skeletal muscle. This suggests that the initial
developmental program for myosin expression in differentiating
skeletal muscle may be related to that for cardiac ventricular
myosin [21]. In a similar study, cardiac ventricular MHC was
found in developing as well as regenerating anterior latissimus
dorsi avian skeletal muscle [22]. In the case of cardiac muscle
though, it was unclear whether the developmental program
involved the co-expression of skeletal as well as cardiac isomyosins.
In the current study, we found that skeletal muscle specific fast
MHC was in fact transiently expressed during the initial
developmental program of the developing fetal myocardium.
Cardiac troponin-I and -T are normally specific to the adult
cardiac muscle. However, cTn-T isoforms have been shown to be
expressed in human skeletal muscle in individuals suffering from
Duchenne muscular dystrophy, polymyositis, and end stage renal
disease [5] and in developing and regenerating rat skeletal muscle
[23]. Fredericks et al. showed that cTn-I and cTn-T are expressed
in adult rat skeletal muscle in response to denervation, but the
protein expression levels were several thousand times lower than in
the heart [24]. Messner et al. showed that mRNA from cTn-T and
cTn-I are expressed in skeletal muscle in patients with Duchenne
muscular dystrophy and several other myopathies [25]. In the
present study, we found that cTn-I was transiently expressed
during the early development of skeletal muscle. To our
knowledge, this is the first comprehensive study of the time course
expression of cTn-I during the normal development of skeletal
muscle. Sutherland et al. examined cTn-I mRNA expression in
the developing rat hindlimb by Northern blot but did not detect
any cTn-I in skeletal muscle [26]. This may be due to the low
sensitivity of Northern blot relative to RT-PCR. We have shown
that cTn-I is expressed in early developing skeletal muscle at both
the gene and protein level and visually shown changes in its
structural organization.
Figure 4. RT-PCR analysis of cardiac and skeletal muscle transcription factors, sk-fMHC, cTn-I mRNA expression. Lane 1: ED13
ventricle, Lane 2: ED20 ventricle; Lane 3: ND0 ventricle; Lane 4: ND4 ventricle; Lane 5: PND10 ventricle; Lane 6: Adult ventricle; Lane 7: ED13 hind
limbs; Lane 8: ED20 hind limbs, Lane 9: ND0 hind limbs; Lane 10: ND4 hind-limbs; Lane 11: PND10 gastrocnemius muscle; Lane 12: Adult
gastrocnemius muscle. We note that ED20 skeletal muscle (hind limbs) mRNA expression patterns are similar to ED20 ventricular myocardium.
doi:10.1371/journal.pone.0040725.g004
Table 1. Cycle to threshold (Ct) Values of cardiac and skeletal muscle transcription factor and structural muscle protein gene
expression of Embryonic day 13 (ED13) ventricular myocardium and skeletal muscle (limbs).
Beta Actin Nkx2.5 GATA4 MyoD Myogenin MYH6 MYH4 cTn-I
Skeletal Muscle 14.560.2 25.860.1 28.660.4 22.560.5 20.860.0 23.460.6 28.960.3 22.960.0
Heart 15.860.1 21.160.2 24.560.2 32.560.2 27.960.1 34.161.6 36.160.9 16.360.1
Although expression levels vary between both types of tissue, their transcriptional and structural gene profiles overlap.
doi:10.1371/journal.pone.0040725.t001
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Figure 5. Changes in mRNA levels of cardiac and skeletal muscle specific transcription factors within ventricular myocardium and
skeletal muscle. Data are expressed as average 6 SD. Cardiac transcription factors, Nkx2.5 and GATA4, and skeletal muscle transcription factor
MyoD expression did not change in ventricular myocardium in adulthood, whereas myogenin expression was significantly decreased in ventricular
myocardium (P,0.05, ANOVA). Nkx2.5 and GATA4 were significantly decreased during development, and MyoD and myogenin were significantly
increased in skeletal muscle during the development (P,0.05). Log10RQ: Relative Quantification of mRNA level compared to the mRNA level in ED13.
The ratio is expressed as logarithm with base value of 10 (Log10).
doi:10.1371/journal.pone.0040725.g005
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As development of the myocardium progressed, sk-fMHC
became negative, and the myocardium then expressed cTn-I.
Conversely, as development of skeletal muscle progressed, cTn-I
became negative, and the skeletal muscle then expressed sk-
fMHC. Fast skeletal muscle is more prone to fatigue, utilizes ATP
quickly, and uses less oxygen, whereas cardiac muscle is made to
resist fatigue and generally needs more oxygen. Thus, from a
physiological standpoint, the benefit of sk-fMHC in the immature
developing fetal myocardium may be shorter and quicker
contraction for quicker blood ejection throughout the system,
which is necessary for supporting rapid fetal growth prior to the
establishment of coronary artery circulation, cardiac autonomic,
and conduction systems. As the myocardium matures, the
contraction pattern shifts towards less rapid but continuous
contraction under aerobic conditions, at which point the coronary
circulation and conduction as well as cardiac autonomic system
are established, and sk-fMHC expression decreases. Continued
expression of sk-fMHC would be detrimental because if fast
muscle tissue were to persist in the postnatal and adult
myocardium, it would fatigue much faster, potentially increasing
the risk of cellular acidosis. A recent study by Rutland and
colleagues reported the expression of embryonic myosin heavy
chain (eMYH), a fast skeletal specific isoform, in the developing
chick heart. Its functional homologue in humans is believed to be
Myh3 [27]. While they did not detect the presence of other skeletal
myosin heavy chain genes in human fetal and adult hearts, we
speculate that sk-fMHC may serve a similar role in rats as Myh3 in
humans during heart development. Moreover, while their study
focused on changes that occur during early development, we place
a specific emphasis on the events that occur during the transition
from late fetal to early postnatal life.
One potential limitation of the current study is the use of the
Sigma MY32 antibody and the lack of a more specific
commercially available antibody. Sigma reports that it stains the
fast (type II) and neonatal myosin molecules found in skeletal
muscle. It is possible that MY32 may cross react with the
Figure 6. Changes in mRNA levels of sk-fMHC, cTn-I, and cardiac a-MHC within ventricular myocardium and skeletal muscle. Data are
expressed as average 6 SD. The sk-fMHC mRNA level was significantly decreased and cTn-I and a-MHC levels were significantly increased in
ventricular myocardium (P,0.05, ANOVA). Conversely, sk-fMHC mRNA level was significantly increased and cTn-I and a-MHC were significantly
decreased in skeletal muscle. Log10RQ: Relative Quantification of mRNA level compared to the value in ED13. The ratio is expressed as logarithm with
base value of 10 (Log10).
doi:10.1371/journal.pone.0040725.g006
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embryonic and neonatal myosin heavy chain isoforms. The
reactivity of this antibody with the embryonic and neonatal forms
has not been fully characterized. However, Lyons et al. have
reported that the embryonic and neonatal forms are not expressed
in the developing mouse embryo heart [28], which would indicate
that sk-fMHC is the only fast skeletal muscle MHC expressed in
the developing heart in rats.
The N-terminal extension of cTn-I contains two phosphoryla-
table serines (Ser-23 and Ser-24), which are targets of protein
kinase A and protein kinase C and are not present in the fast and
slow skeletal isoforms of troponin I [29]. These additional sites
confer a greater degree of regulation of Calcium sensitivity and
contractility [29,30]. Thus, the presence of the cardiac isoform in
developing skeletal muscle might provide an additional level of
control of muscle activity prior to the full development of the
nervous system, which would increase energy efficiency in the
metabolically active developing fetus.
Real-time RT-PCR analysis of gene expression in the develop-
ing heart and skeletal muscle supports the idea of developmental
commonality between both types of tissue. Cardiac specific genes
such as Nkx2.5, GATA4, a-MHC, and cTn-I are expressed in
developing skeletal muscle. Expression levels of certain genes
within the heart and skeletal muscle change over time, while
others, notably Nkx2.5 and GATA4 within the myocardium,
remain relatively constant over time. Interestingly, sk-fMHC
mRNA continues to be expressed at low levels in adult
myocardium, and cTn-I mRNA continues to be expressed at
low levels in adult skeletal muscle, despite the absence of protein
expression. It is possible that these genes are post-transcriptionally
suppressed in adulthood, but the continued expression at the
transcript level provides a faster means of response in response to
external events such as injury such as myocardial infarction, which
leads to recapitulation of the fetal gene program. Sassoon et al.
reported that MyoD and myogenin were detected by in-situ
hybridization in embryonic skeletal muscle but not heart [31].
However, they only specify that they examined expression in the
heart at embryonic day 7.5 during heart tube formation. They do
not specify the range of time points that they examined. MyoD
and myogenin may only be expressed in the heart during later
development, as our results indicate. Di Lisi et al. reported that
GATA4 is expressed in C2C12 muscle cells at the transcript level
but not at the protein level [32]. However, they used C2C12 cells
terminally differentiated into myotubes in vitro under convention-
al 2D culture for their analysis, which does not accurately
represent in vivo development. Overall, our results suggest a
shared developmental program between skeletal and cardiac
muscle, which is lost as they mature into distinct tissue types. We
speculate that skeletal muscle development (maturation) occurs at
later development compared to the cardiac muscle, and the
skeletal muscle differentiation temporarily requires the cardiac
muscle phenotype (cyclic twitch) to acquire the function towards
highly controlled contraction and relaxation under the regulation
of the nervous system, which may be supported by the previous
report from Fredericks et al. [24].
Consistent with our pervious study, we showed that MDSCs
isolated from juvenile rat skeletal muscle differentiate into
cardiomyocyte like cells in a 3D collagen gel bioreactor (MDSC-
3DGB) [15]. With respect to the current work, the MDSC-3DGB
appeared to expresses cTn-I at higher levels than ED20 skeletal
muscle but lower than ED20 myocardium. The findings presented
here support the idea that MDSCs have the capacity to
differentiate into a more cardiac phenotype in-vitro. Fate decisions
are ultimately influenced by biochemical and biomechanical
signals from the environment. Providing the appropriate environ-
ment for stem cell differentiation remains a topic of ongoing
research.
In conclusion, the current study provides new evidence that
skeletal muscle specific fast myosin heavy chain is transiently
expressed in the developing immature myocardium, and cardiac
troponin I is transiently expressed in developing skeletal muscle.
These findings shed light on a previously unknown aspect of
muscle development. Further studies are necessary to examine the
role of these contractile proteins during development and how
they are regulated.
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